Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells therapy(Shanghai Zhongshan Hospital)

N/A

Report date: 2025/01/08 20:00:42

Base Information

Drug NameGene modified anti-IL1RAP Chimeric Antigen Receptor T Cells therapy(Shanghai Zhongshan Hospital)
Drug Alias NameIL1RAP-targeting Chimeric Antigen Receptor T Cells therapy(Shanghai Zhongshan Hospital)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-Interleukin-1 receptor accessory proteinT lymphocyte replacements
TargetsInterleukin-1 receptor accessory protein
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Zhongshan Hospital
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Zhongshan Hospital
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A